You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,664,688

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,664,688

Title:	Method of identifying risk for thyroid disorder
Abstract:	A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.
Inventor(s):	Margolin; David H. (Somerville, MA)
Assignee:	GENZYME CORPORATION (Cambridge, MA)
Application Number:	13/705,944
Patent Claims:	1. A method for treating a multiple sclerosis (MS) patient, comprising: (a) selecting an MS patient for treatment with an anti-CD52 antibody, wherein a biological sample obtained from the patient prior to the treatment has tested negative for antibodies against thyroid peroxidase or thyroid microsomes; and (b) administering the anti-CD52 antibody to the patient. 2. The method of claim 1, wherein the patient has relapsing remitting multiple sclerosis (MS). 3. The method of claim 1 or 2, wherein the anti-CD52 antibody is alemtuzumab. 4. The method of claim 1 or 2, wherein the anti-CD52 antibody comprises one or more CDRs having an amino acid sequence identical to the amino acid sequence of a CDR of alemtuzumab. 5. The method of claim 1, wherein the thyroid disorder is selected from the group consisting of: hypothyroidism, hyperthyroidism, Graves' disease, autoimmune thyroiditis and a combination thereof.

Details for Patent 9,664,688

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001	⤷ Try a Trial	2027-02-16
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014	⤷ Try a Trial	2027-02-16
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004	⤷ Try a Trial	2027-02-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.